[How to analyze and prevent the risks associated with the use of erythropoiesis stimulating agents].
Erythropoiesis stimulating agents (ESAs) represent a significant cost for health care establishments, which are now subjected to new restrictions on how these agents can be dispensed, as laid down in the Decree of 24th August 2005 relating to a contract for the proper use of drugs, medical products and services. To optimize the treatment plan, ensure that these agents are used properly and satisfy the new requirements, a multidisciplinary expert group has drawn up a guide for health professionals which presents: important points specifically addressing the modalities of administration of ESAs in patients with renal disease treated by hemodialysis; a risk assessment which has helped identify preventive measures; proposals for preventive or corrective actions against medication risks or errors; an internal frame of reference for use in drawing up protocols and evaluating practices. This guide should promote a better use of ESAs once it is adopted by health care establishments, who must adapt it to their internal operations and provide suitable informational education. Training the relevant players in how to assess professional practices, together with the work of the multidisciplinary study group, are key factors that should help make this initiative a success.
Dussert
Sandrine
S
Ingénieur qualité, Toulouse, France. sdussert@club-internet.fr
Ferrandini
Corinne
C
Hurot
Jean-Marc
JM
Magnam
Jöelle
J
Ortiz
Jean-Paul
JP
D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000009:adverse effects / Q000627:therapeutic use*; D006397:Hematinics / Q000627:therapeutic use; D006801:Humans; D007676:Kidney Failure, Chronic / Q000628:therapy*; D017410:Practice Guidelines as Topic; D011994:Recombinant Proteins; D006435:Renal Dialysis
D006397:Hematinics; D011994:Recombinant Proteins; C103998:epoetin beta; D004921:Erythropoietin; D000068817:Epoetin Alfa